These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 16969893)

  • 1. Optimal designs for estimating the most successful dose.
    Zohar S; O'Quigley J
    Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
    He W; Liu J; Binkowitz B; Quan H
    Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
    Seegers V; Chevret S; Resche-Rigon M
    Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved up-and-down designs for phase I trials.
    Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
    Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose escalation trial designs based on a molecularly targeted endpoint.
    Hunsberger S; Rubinstein LV; Dancey J; Korn EL
    Stat Med; 2005 Jul; 24(14):2171-81. PubMed ID: 15909289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
    Wang M; Day R
    J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-finding in phase I clinical trials based on toxicity probability intervals.
    Ji Y; Li Y; Nebiyou Bekele B
    Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneously optimizing dose and schedule of a new cytotoxic agent.
    Braun TM; Thall PF; Nguyen H; de Lima M
    Clin Trials; 2007; 4(2):113-24. PubMed ID: 17456511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An optimization algorithm for designing phase I cancer clinical trials.
    Jiang H; Liu Y; Su Z
    Contemp Clin Trials; 2008 Mar; 29(2):102-8. PubMed ID: 17681867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian dose finding design for dual endpoint phase I trials.
    Loke YC; Tan SB; Cai Y; Machin D
    Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of dose-finding studies to observation errors.
    Zohar S; O'Quigley J
    Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
    Ivanova A; Wang K
    Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision-theoretic designs for dose-finding clinical trials with multiple outcomes.
    Fan SK; Wang YG
    Stat Med; 2006 May; 25(10):1699-714. PubMed ID: 16217860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An approach to meta-analysis of dose-finding studies.
    Zohar S; Katsahian S; O'Quigley J
    Stat Med; 2011 Jul; 30(17):2109-16. PubMed ID: 21344473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.